Guangsheng Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guangsheng Zhao has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dong Wang
Dalian Medical University, Dalian, China
2 shared publications - Guangji Yu
Department of Interventional Therapy, Linyi Cancer Hospital, Linyi, China
2 shared publications Qingdong Wang
Cancer Interventional Center, Linyi Cancer Hospital
2 shared publicationsSong Liu
Cancer Interventional Center, Linyi Cancer Hospital
2 shared publications- Bu Qiang Zhuang
Department of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University
1 shared publication Changqing Liu
Dalian Medical University, Dalian, China
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1784905
Efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study
Objective: To evaluate the clinical efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with unresectable gastrointestinal stromal tumor (GIST) liver metastases after the failure of targeted therapy. Methods: 77 patients with unresectable GIST liver metastases who had failed at least two lines of targeted therapy were retrospectively enrolled from three centers between January 2022 to December 2024. Based on their treatment regimen, patients were divided into an observation group (n=34) and a control group (n=43). The control group continued receiving tyrosine kinase inhibitors (TKIs) or best supportive care (BSC). The observation group underwent DEB-TACE followed by TKI therapy or BSC. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS), progression-free survival (PFS), and adverse events during treatment were recorded and analyzed. Results: At the first efficacy evaluation, the observation group exhibited an objective response rate (ORR) of 94.12% (10 complete response [CR], 22 partial response [PR]) and a disease control rate (DCR) of 100%. In the control group, the ORR was 4.65% (2 PR) and the DCR was 39.53%. The median PFS (liver) was significantly longer in the observation group (11.0 months) than in the control group (5.0 months; P < 0.001). The median OS was also longer in the observation group (18.0 months vs. 12.0 months; P < 0.001). Prognostic analysis indicated that better baseline liver function, fewer prior lines of therapy, and DEB-TACE treatment were associated with improved outcomes. Adverse events in the observation group were primarily related to post-embolization syndrome and transient liver injury, with no increase in targeted therapy-related toxicity. Conclusion: DEB-TACE demonstrates favorable efficacy and a manageable safety profile in patients with unresectable GIST liver metastases after targeted therapy failure, representing a safe and feasible treatment option worthy of clinical application.
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1784905
Open AccessEfficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study
Objective: To evaluate the clinical efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with unresectable gastrointestinal stromal tumor (GIST) liver metastases after the failure of targeted therapy. Methods: 77 patients with unresectable GIST liver metastases who had failed at least two lines of targeted therapy were retrospectively enrolled from three centers between January 2022 to December 2024. Based on their treatment regimen, patients were divided into an observation group (n=34) and a control group (n=43). The control group continued receiving tyrosine kinase inhibitors (TKIs) or best supportive care (BSC). The observation group underwent DEB-TACE followed by TKI therapy or BSC. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS), progression-free survival (PFS), and adverse events during treatment were recorded and analyzed. Results: At the first efficacy evaluation, the observation group exhibited an objective response rate (ORR) of 94.12% (10 complete response [CR], 22 partial response [PR]) and a disease control rate (DCR) of 100%. In the control group, the ORR was 4.65% (2 PR) and the DCR was 39.53%. The median PFS (liver) was significantly longer in the observation group (11.0 months) than in the control group (5.0 months; P < 0.001). The median OS was also longer in the observation group (18.0 months vs. 12.0 months; P < 0.001). Prognostic analysis indicated that better baseline liver function, fewer prior lines of therapy, and DEB-TACE treatment were associated with improved outcomes. Adverse events in the observation group were primarily related to post-embolization syndrome and transient liver injury, with no increase in targeted therapy-related toxicity. Conclusion: DEB-TACE demonstrates favorable efficacy and a manageable safety profile in patients with unresectable GIST liver metastases after targeted therapy failure, representing a safe and feasible treatment option worthy of clinical application.
- Open Access
- 24 January 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-12
Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching
To investigate the efficacy and safety of drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE) combined with systemic chemotherapy and immune checkpoint inhibitors in the treatment of unresectable intrahepatic cholangiocarcinoma. This study used retrospective cohort analysis to collect the clinical data of 209 patients with unresectable intrahepatic cholangiocarcinoma treated in Linyi Cancer Hospital, Affiliated Zhongshan Hospital of Dalian University, Affiliated Central Hospital of Dalian University of Technology from January 2020 to January 2024. The patients were divided into observation group and control group based on their treatment plans. The observation group was treated with DEB-TACE combined with systemic chemotherapy and immune checkpoint inhibitor, and the control group was treated with simple systemic chemotherapy and immune checkpoint inhibitor. Based on propensity score matching analysis, the clinical treatment efficacy, survival prognosis, and incidence of adverse reactions of two groups of patients were evaluated. 82 patients in the observation group received DEB-TACE combined with systemic chemotherapy and immune checkpoint inhibitors, The control group of 127 patients were treated with systemic chemotherapy and immune checkpoint inhibitors. After a propensity score matching analysis to control for the consistency of patient age, sex, tumor size, tumor number, Child grade, ECOG score, and tumor stage. Propensity score matching analysis created 71 pairs of patients in 2 groups. The objective response rate (ORR, 76.06%) and disease control rate (DCR, 97.18%) in the observed group were significantly higher than that in the control group (52.11%, 85.92%), Progression-free survival (PFS, 10 months) and overall survival (OS, 17 months) were higher than the control group (8 months, 11 months). The Cox proportional hazards model analysis revealed that, Child grade and treatment modality were independent predictors of PFS and OS in patients. The adverse effects during treatment were similar in the two groups, with no statistical difference. Compared with systemic therapy alone (systemic chemotherapy + immune checkpoint inhibitor), combined DEB-TACE improves the tumor control rate of patients with unresectable intrahepatic cholangiocarcinoma, extends the survival time and without increasing treatment-related adverse effects, which is a safe and feasible treatment modality.
- 24 January 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-12
Open AccessEfficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching
To investigate the efficacy and safety of drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE) combined with systemic chemotherapy and immune checkpoint inhibitors in the treatment of unresectable intrahepatic cholangiocarcinoma. This study used retrospective cohort analysis to collect the clinical data of 209 patients with unresectable intrahepatic cholangiocarcinoma treated in Linyi Cancer Hospital, Affiliated Zhongshan Hospital of Dalian University, Affiliated Central Hospital of Dalian University of Technology from January 2020 to January 2024. The patients were divided into observation group and control group based on their treatment plans. The observation group was treated with DEB-TACE combined with systemic chemotherapy and immune checkpoint inhibitor, and the control group was treated with simple systemic chemotherapy and immune checkpoint inhibitor. Based on propensity score matching analysis, the clinical treatment efficacy, survival prognosis, and incidence of adverse reactions of two groups of patients were evaluated. 82 patients in the observation group received DEB-TACE combined with systemic chemotherapy and immune checkpoint inhibitors, The control group of 127 patients were treated with systemic chemotherapy and immune checkpoint inhibitors. After a propensity score matching analysis to control for the consistency of patient age, sex, tumor size, tumor number, Child grade, ECOG score, and tumor stage. Propensity score matching analysis created 71 pairs of patients in 2 groups. The objective response rate (ORR, 76.06%) and disease control rate (DCR, 97.18%) in the observed group were significantly higher than that in the control group (52.11%, 85.92%), Progression-free survival (PFS, 10 months) and overall survival (OS, 17 months) were higher than the control group (8 months, 11 months). The Cox proportional hazards model analysis revealed that, Child grade and treatment modality were independent predictors of PFS and OS in patients. The adverse effects during treatment were similar in the two groups, with no statistical difference. Compared with systemic therapy alone (systemic chemotherapy + immune checkpoint inhibitor), combined DEB-TACE improves the tumor control rate of patients with unresectable intrahepatic cholangiocarcinoma, extends the survival time and without increasing treatment-related adverse effects, which is a safe and feasible treatment modality.
- 1 February 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (3) , 1215-1222
The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis
Background This study aimed to investigate the efficacy and safety of CalliSpheres drug-eluting beads transarterial chemoembolization (DEB-TACE) combined with regorafenib in the second-line treatment of unresectable hepatocellular carcinoma. Methods A retrospective analysis was made of 34 patients with unresectable hepatocellular carcinoma (HCC) that had progressed after first-line treatment in Linyi Tumor Hospital from October 2019 to June 2021. These patients were divided into observation group (n = 15) and control group (n = 19) based on their treatment plans, who were respectively treated with regorafenib alone and regorafenib combined with DEB-TACE. The objective response rate (ORR) and the disease control rate (DCR) were evaluated by the modified Response Evaluation Criteria in Solid Tumors (mRECIST), and the progression-free survival (PFS) and the overall survival (OS) were calculated; the factors influencing PFS and OS of patients were analyzed by the Cox proportional hazards model; and the adverse reactions to the treatments were observed and recorded. Results After 2 months of treatment, the ORR and the DCR of the observation group were 73.3% (11/15) and 86.7% (13/15) respectively, both higher than 10.5% (2/19) and 47.4% (9/19) of the control group. Their differences are statistically significant (P < 0.05). There were no statistically significant differences in the incidences of regorafenib-related adverse reactions including hand-foot skin reactions, fatigue, hypertension, diarrhea, and proteinuria between the two groups (P > 0.05). In the observation group, the main adverse reactions to DEB-TACE such as fever, pain, nausea, and vomiting were relieved after symptomatic treatment, and no serious complications such as ectopic embolization of CalliSpheres drug-eluting beads occurred. As of July 31, 2022, the median follow-up time was 12.5 months, and the average was (14.00 ± 5.69) months. The median PFS was 9 months in the observation group, and 6 months in the control group, presenting a statistically significant difference (P < 0.05), and the median OS was 18 months in the observation group, and 12 months in the control group, also presenting a statistically significant difference (P < 0.05). The results of monofactor prognostic analysis showed that Child grade, AFP level, and treatment method had an influence on the PFS and the OS of liver cancer patients receiving regorafenib second-line treatment (P < 0.05), and the results of multifactor prognostic analysis showed that child grade and treatment method independently influenced the PFS of patients, while treatment method independently influenced the OS of patients (P < 0.05). Conclusions DEB-TACE combined with regorafenib is safe and feasible in the treatment of unresectable HCC, with good efficacy and mild adverse reactions.
- 1 February 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (3) , 1215-1222
The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis
Background This study aimed to investigate the efficacy and safety of CalliSpheres drug-eluting beads transarterial chemoembolization (DEB-TACE) combined with regorafenib in the second-line treatment of unresectable hepatocellular carcinoma. Methods A retrospective analysis was made of 34 patients with unresectable hepatocellular carcinoma (HCC) that had progressed after first-line treatment in Linyi Tumor Hospital from October 2019 to June 2021. These patients were divided into observation group (n = 15) and control group (n = 19) based on their treatment plans, who were respectively treated with regorafenib alone and regorafenib combined with DEB-TACE. The objective response rate (ORR) and the disease control rate (DCR) were evaluated by the modified Response Evaluation Criteria in Solid Tumors (mRECIST), and the progression-free survival (PFS) and the overall survival (OS) were calculated; the factors influencing PFS and OS of patients were analyzed by the Cox proportional hazards model; and the adverse reactions to the treatments were observed and recorded. Results After 2 months of treatment, the ORR and the DCR of the observation group were 73.3% (11/15) and 86.7% (13/15) respectively, both higher than 10.5% (2/19) and 47.4% (9/19) of the control group. Their differences are statistically significant (P < 0.05). There were no statistically significant differences in the incidences of regorafenib-related adverse reactions including hand-foot skin reactions, fatigue, hypertension, diarrhea, and proteinuria between the two groups (P > 0.05). In the observation group, the main adverse reactions to DEB-TACE such as fever, pain, nausea, and vomiting were relieved after symptomatic treatment, and no serious complications such as ectopic embolization of CalliSpheres drug-eluting beads occurred. As of July 31, 2022, the median follow-up time was 12.5 months, and the average was (14.00 ± 5.69) months. The median PFS was 9 months in the observation group, and 6 months in the control group, presenting a statistically significant difference (P < 0.05), and the median OS was 18 months in the observation group, and 12 months in the control group, also presenting a statistically significant difference (P < 0.05). The results of monofactor prognostic analysis showed that Child grade, AFP level, and treatment method had an influence on the PFS and the OS of liver cancer patients receiving regorafenib second-line treatment (P < 0.05), and the results of multifactor prognostic analysis showed that child grade and treatment method independently influenced the PFS of patients, while treatment method independently influenced the OS of patients (P < 0.05). Conclusions DEB-TACE combined with regorafenib is safe and feasible in the treatment of unresectable HCC, with good efficacy and mild adverse reactions.